Results 131 to 140 of about 47,170 (292)
The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis
Epileptic Disorders, EarlyView.Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino +5 more
wiley +1 more source
Biopharmaceuticals: Priority Sector Report
, 2019 The Biopharmaceuticals emerging industry is the result of an evolution of the traditional pharmaceutical industry that emerged in the late 1800s, mainly based on chemical production. The industry has incorporated the more recent emergence of biotechnology developed on living cells and molecules, stemming from key innovations in the 1970s and 1980s ...
openaire +2 more sources
Epilepsia, EarlyView.Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer +7 more
wiley +1 more source
Epilepsia, EarlyView.Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer +7 more
wiley +1 more source
Securing the Biopharmaceutical Frontier
In the contemporary European biopharmaceutical landscape, the imperative for accelerated innovation and global market stability is being fundamentally redefined by the escalating complexity of the digital threat landscape.
Joahana Soutiroye
core +1 more source
Epilepsia, EarlyView.Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee +20 more
wiley +1 more source
Open Innovation Strategies In The Biopharmaceutical Industry
, 2015 Open Innovation Strategies In The Biopharmaceutical ...
RUSSO SPENA, TIZIANA, DI PAOLA, NADIA
core
Epileptic drop attacks: More than just atonic seizures
Epilepsia Open, EarlyView.Abstract “Drop attacks” are not officially defined by the International League Against Epilepsy. Seizures are characterized by a sudden loss of control over the trunk and posture, leading to falls and injuries, and resolving within a few seconds. Accurately diagnosing the type of seizure is usually difficult due to limitations in clinical documentation
Tomonori Ono +3 more
wiley +1 more source
Strategic aspects of staffing industrial biopharmaceutical companies
The role of biotechnology in the development of the Russian economy has been identified. The results ofthe analysis ofthe main trends in the development ofbiopharmaceutics and biomedicine were presented.
M. V. Duljasova, A. S. Glazkova
core +3 more sources
Epilepsia Open, EarlyView.Abstract Objective Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in otherwise healthy patients with epilepsy; about 70% occurs during sleep, and nearly 90% of patients are found prone (face‐down). Following a nocturnal seizure, terminal apnea occurs between 2.5 and 10.8 min postictally (median ~ 5 min), defining a narrow but
Jong Woo Lee +6 more
wiley +1 more source